New measures for the security assessment of data transfers from China to other countries could make it harder for international pharma companies with China operations to transfer health data out of the country. Lianying Wang explains.
About Lianying Wang
Entries by Lianying Wang
As the year approaches its halfway point, Chinese government accelerates the legislation for cross-border data transfers.
Certification by a professional institution is one of the mechanisms permitted under China’s Personal Information Protection Law (PIPL) to legitimize cross-border transfers of personal information. Other permitted mechanisms include governmental […]
The concept of “important data” is a cornerstone of China’s data regulatory regime. The Cyber Security Law (2017) (the CSL) prohibits operators of critical information infrastructures (CIIs) from transferring their […]